Incyte (INCY) Tops Q3 EPS by 46c
Incyte (NASDAQ: INCY) reported Q3 EPS of $1.18, $0.46 better than the analyst estimate of $0.72. Revenue for the quarter came in at $813 million versus the consensus estimate of $738.52 million.
2021 Financial Guidance:
The Company has reaffirmed its full year 2021 financial guidance, as detailed below. Guidance does not include revenue from Opzelura in the U.S., Minjuvi in Europe or the impact of any potential future strategic transactions.
|
|
| |
| Current | Previous | |
Jakafi net product revenues | $2,125 - $2,170 million | Unchanged | |
Other Hematology/Oncology net product revenues | $155 - $170 million | Unchanged | |
GAAP Cost of product revenues | 6 – 7% of net product revenues | Unchanged | |
Non-GAAP Cost of product revenues1 | 5 – 6% of net product revenues | Unchanged | |
GAAP Research and development expenses | $1,350 - $1,390 million | Unchanged | |
Non-GAAP Research and development expenses2 | $1,220 - $1,250 million | Unchanged | |
GAAP Selling, general and administrative expenses | $725 - $755 million | Unchanged | |
Non-GAAP Selling, general and administrative expenses3 | $655 - $680 million | Unchanged |
1 Adjusted to exclude the amortization of licensed intellectual property for Iclusig relating to the acquisition of the European business of ARIAD Pharmaceuticals, Inc. and the estimated cost of stock-based compensation.
2 Adjusted to exclude the estimated cost of stock-based compensation.
3 Adjusted to exclude the estimated cost of stock-based compensation and legal settlements.
For earnings history and earnings-related data on Incyte (INCY) click here.